Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Arteaus Therapeutics

Request full access

A biotechnology development company creating new therapies to treat migraine.

Cambridge, United StatesFounded 2011Biotech & Life Sciences

About Arteaus Therapeutics

Arteaus Therapeutics, LLC operated as a specialized biotechnology development company with a clear, asset-centric focus on creating a new therapy for migraine prevention. Founded in 2011 by Scott Chappell, with David Grayzel, MD, serving as CEO, the company was established through a strategic collaboration with Eli Lilly and Company. This venture was a prime example of a "built-to-buy" model, initiated by Atlas Venture Development Corp (AVDC), a unit of Atlas Venture, alongside OrbiMed.

The company's formation was centered on a single asset: a calcitonin gene-related peptide (CGRP) antibody, LY2951742, which was originally discovered by scientists at Eli Lilly. Arteaus was launched with an $18 million Series A investment from Atlas Venture and OrbiMed to exclusively license and advance this antibody through clinical development. The business model was designed to be capital-efficient, utilizing a virtual team to take the drug through to a key value inflection point—specifically, a Phase 2 proof-of-concept study. This approach enabled a larger pharmaceutical company to externalize a portion of its R&D, leveraging the entrepreneurial and focused structure of a small biotech firm.

Arteaus' sole product was the antibody LY2951742 (now known as galcanezumab or Emgality), designed to prevent migraine headaches. This therapeutic antibody works by targeting and blocking CGRP, a sensory neuropeptide implicated in the vascular and inflammatory processes that contribute to migraines. The intended benefit for patients suffering from frequent migraines was a reduction in the frequency of attacks through a self-administered, once-monthly injection. After successfully completing the Phase 2 trial within approximately 2.5 years, demonstrating the drug's potential efficacy and safety, Eli Lilly exercised its option to reacquire the full development rights in January 2014 for approximately $57.1 million. Following the acquisition, Arteaus Therapeutics was wound down, having fulfilled its specific mission. The investors later sold their royalty interests on the drug's sales to Royalty Pharma in 2019 for $260 million.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
54.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Developer Tools, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2C

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VC✓Equity / VC Jul 2012 $12M $48M Atlas Venture · OrbiMed —
EARLY VC✓Equity / VC Oct 2011 $18M $72M Atlas Venture · OrbiMed —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Arteaus Therapeutics website traffic

Latest recorded traffic for Arteaus Therapeutics is 230 monthly website visits.

Latest monthly visits230
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Arteaus Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Arteaus Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Arteaus Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Arteaus Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.